Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products ...
SurvivorNet on MSN
Diagnosing muscle-invasive bladder cancer: The initial work-up
When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Sacituzumab Govitecan Plus Pembrolizumab Shows Promise for Bladder Sparing in Muscle-Invasive Cancer
Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...
GlobalData on MSN
J&J reports positive data for Erda-iDRS in bladder cancer
Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
Most people don’t think about their bladder very often. But as you get older, it’s something that requires a little bit more attention. Here’s what you need to know about how your bladder changes as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results